Sepset study to fast track diagnosis of sepsis

Sepset Biosciences Inc has started a multi-country and multi-center clinical study to develop faster and more accurate identification of patients afflicted with sepsis. The study is expected to assist in validating and refining the proprietary gene signature of Sepset, which is a spin-out of the Centre for Drug Research and Development (CDRD). A successful development of a novel rapid diagnostic test will aid healthcare professionals in providing targeted treatment of sepsis in a much shorter period of time. Sepsis is a serious condition caused by an infection of the immune system, creating an imbalance, which leads to multiple organ failure and death. It takes roughly twenty-hours using the current methods to diagnose sepsis. But this duration is long enough to result in tissue damage, organ failure, and death. The number of deaths due to sepsis rises 8% every hour of delayed treatment. However, 80% of the deaths could be prevented with faster diagnosis and treatment. Globally, the number of patients hospitalized has reached more than 18 million yearly.